Abstract
Lazertinib (Laz) is an oral, potent, brain-penetrant 3rd generation EGFR-TKI targeting T790M and activating EGFR mutations while sparing WT EGFR. Amivantamab (Ami) is an EGFR-MET bispecific antibody with immune-cell directing properties. This study (NCT04077463) evaluates the safety, tolerability, PK of Laz (Ph1) or in combinations with Ami (Ph1b combo) in Japan, and to further characterize this combination globally (Ph1b expansion) in advanced EGFR-mutant NSCLC patients (pts). Here, we present the Japanese (JPN) Ph1/1b combo data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
